Aptevo's mipletamig triplet shows 93% clinical benefit in TP53-mutated frontline AML
APVO is trading near its 52-week low of $2.301 (5.1% below the low) on elevated volume (15× avg).
Summary
Aptevo announced a 93% clinical benefit rate with its mipletamig triplet in TP53-mutated frontline AML, nearly double the published benchmark for ven/aza alone.
Key Events · Product Development and Regulatory · APVO
-
93% Clinical Benefit Rate in TP53-Mutated AML
13 of 14 evaluable TP53-mutated frontline AML patients treated with mipletamig plus venetoclax and azacitidine experienced clinical benefit.
-
79% CR/CRi Rate Nearly Doubles Benchmark
11 patients achieved CR or CRi (79%), including 9 complete remissions, versus a published 41% composite remission rate for ven/aza alone in TP53-mutated AML.
-
RAINIER Trial Timeline
Phase 1b dose optimization is expected to complete by year-end 2026, with regulatory interaction planned for 1H27 to determine next steps.
-
High-Unmet-Need Patient Population
TP53-mutated AML is one of the most difficult-to-treat forms of AML, with historically lower remission rates and poorer outcomes.
Analysis · APVO · Life Sciences
Aptevo reported a 93% clinical benefit rate and 79% CR/CRi rate in 14 evaluable TP53-mutated frontline AML patients treated with mipletamig plus venetoclax and azacitidine. That nearly doubles the published 41% composite remission rate for ven/aza alone in this historically difficult-to-treat population. The data strengthens the case for mipletamig as a frontline therapy in a high-unmet-need subgroup, with the RAINIER dose-optimization phase expected to complete by year-end and regulatory interaction planned for 1H27. For a micro-cap company trading near its 52-week low with going-concern doubts, positive clinical data is a meaningful value driver.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 36.1% of the 1758 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.05%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, APVO was trading at $2.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7M. The 52-week trading range was $2.30 to $48.78. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.